Patents by Inventor Cang Zhang
Cang Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230037219Abstract: A memory management method and system for an Android system, and a storage medium. The Android system includes a framework layer, a native layer and a kernel layer; the memory management system includes a service component on the framework layer, a memory manager on the native layer and an interface reclaimer on the kernel layer; the service component communicates with the memory manager and the interface reclaimer, respectively; the memory manager is configured to determine a memory event based on pressure stall information (PSI) obtained from a hook on a memory reclaim path, and report the memory event to the service component; and the service component is configured to call the interface reclaimer in response to the memory event being an event of reclaiming memory based on a process, and shut down a corresponding process interface by the interface reclaimer.Type: ApplicationFiled: February 25, 2022Publication date: February 2, 2023Inventors: Cang ZHANG, Ju WANG, Zhihao ZHANG, Xueni CHEN
-
Patent number: 9963480Abstract: A novel nucleoside phosphoramidate compound of the formula below, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection, and having a good anti-HCV effect; a pharmaceutical composition having the compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof:Type: GrantFiled: March 6, 2014Date of Patent: May 8, 2018Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.Inventors: Yong Wang, Liwen Zhao, Xian Zhang, Sheng Bi, Yiping Gao, Hongyan Chen, Dezhong Wang, Yang Nan, Cang Zhang, Yuxiu Li, Di Zhang
-
Patent number: 9512108Abstract: The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.Type: GrantFiled: December 26, 2014Date of Patent: December 6, 2016Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.Inventors: Yong Wang, Liwen Zhao, Dezhong Wang, Haiping Zhou, Xian Zhang, Hongyan Chen, Di Zhang, Cang Zhang
-
Publication number: 20160297804Abstract: The present invention belongs to the field of chemical pharmaceuticals, and specifically relates to compounds represented by formula I having a 9,9,10,10-tetrafluoro-9,10-dihydrophenanthrene structure and being able to inhibit hepatitis C virus activity, or a pharmaceutically acceptable salt, isomer, solvate, crystal or prodrug of said compounds, a pharmaceutical composition containing said compounds, and an application of said compounds or composition in the preparation of a drug. The compounds of the present invention have a good HCV inhibitory effect.Type: ApplicationFiled: December 26, 2014Publication date: October 13, 2016Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.Inventors: Yong WANG, Liwen ZHAO, Dezhong WANG, Haiping ZHOU, Xian ZHANG, Hongyan CHEN, Di ZHANG, Cang ZHANG
-
Patent number: 9255107Abstract: In the field of pharmaceutical chemistry compounds of general formula I having heteroaryl alkynyl moiety or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, and pharmaceutical compositions including these compounds, as well as uses of these compounds and compositions thereof in the manufacture of a medicament. The compounds have a strong inhibitory effect on BCR-ABL tyrosine kinase and are useful for treating diseases, such as tumors.Type: GrantFiled: November 27, 2013Date of Patent: February 9, 2016Assignee: NANJING SANHOME PHARMACEUTICAL CO., LTD.Inventors: Yong Wang, Liwen Zhao, Di Zhang, Feng Wu, Sheng Bi, Yiping Gao, Hongbin Chen, Hongyan Chen, Cang Zhang, Yang Nan, Yang Liu
-
Publication number: 20150361123Abstract: A novel nucleoside phosphoramidate compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof for the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection is provided. The pharmaceutical composition having the compound, or a stereoisomer, salt, hydrate, solvate or crystal thereof and a use of the compound or the composition in the treatment of Flaviviridae family viral infection, especially hepatitis C viral infection. The compound has a good anti-HCV effect.Type: ApplicationFiled: March 6, 2014Publication date: December 17, 2015Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTDInventors: Yong WANG, Liwen ZHAO, Xian ZHANG, Sheng BI, Yiping GAO, Hongyan CHEN, Dezhong WANG, Yang NAN, Cang ZHANG, Yuxiu LI, Di ZHANG
-
Publication number: 20150299202Abstract: In the field of pharmaceutical chemistry compounds of general formula I having heteroaryl alkynyl moiety or pharmaceutically acceptable salts, isomers, solvates, crystals or prodrugs thereof, and pharmaceutical compositions including these compounds, as well as uses of these compounds and compositions thereof in the manufacture of a medicament. The compounds have a strong inhibitory effect on BCR-ABL tyrosine kinase and are useful for treating diseases, such as tumors.Type: ApplicationFiled: November 27, 2013Publication date: October 22, 2015Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.Inventors: Yong WANG, Liwen ZHAO, Di ZHANG, Feng WU, Sheng BI, Yiping GAO, Hongbin CHEN, Hongyan CHEN, Cang ZHANG, Yang NAN, Yang LIU
-
Patent number: 9139574Abstract: The present invention relates to imidazole, oxazole and thiazole derivatives of tumor-targeted drug combretastatin A4, and phosphate esters, sulfonate esters or pharmaceutically acceptable salts, glycoside derivatives, solvates thereof, wherein the A-ring comprises a 3,5-dimethoxyphenyl group having a substituent at the 4-position. The pharmacological activity assays have demonstrated that the compounds of the present invention have good in vitro anti-tumor activity and excellent tubulin inhibitory effect.Type: GrantFiled: July 4, 2012Date of Patent: September 22, 2015Assignee: Nanjing Sanhome Pharmaceutical Co., Ltd.Inventors: Yong Wang, Cang Zhang, Xiaorong Liu, Yan Zhang, Yunyun Wang, Wenping Zhang
-
Publication number: 20150152088Abstract: The present invention belongs to the field of pharmaceutical chemistry, and specifically relates to compounds having an alkynyl heteroaromatic ring structure and pharmaceutically acceptable salts, stereoisomers, N-oxides, solvates, or prodrugs thereof, and pharmaceutical compositions comprising these compounds, as well as uses of these compounds and compositions in the manufacture of a medicament. The compounds of the present invention and the pharmaceutically acceptable salts, stereoisomers, N-oxides, solvates or prodrugs thereof and the pharmaceutical compositions comprising the compounds have better anti-tumor activity.Type: ApplicationFiled: September 12, 2013Publication date: June 4, 2015Applicant: Nanjing Sanhome Pharmaceutical Co., Ltd.Inventors: Yong Wang, Liwen Zhao, Wenping Zhang, Hongyan Chen, Sheng Bi, Yiping Gao, Hongbin Chen, Yang Liu, Xin Xu, Cang Zhang
-
Publication number: 20140128384Abstract: The present invention relates to imidazole, oxazole and thiazole derivatives of tumor-targeted drug combretastatin A4, and phosphate esters, sulfonate esters or pharmaceutically acceptable salts, glycoside derivatives, solvates thereof, wherein the A-ring comprises a 3,5-dimethoxyphenyl group having a substituent at the 4-position. The pharmacological activity assays have demonstrated that the compounds of the present invention have good in vitro anti-tumor activity and excellent tubulin inhibitory effect.Type: ApplicationFiled: July 4, 2012Publication date: May 8, 2014Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.Inventors: Yong Wang, Cang Zhang, Xiaorong Liu, Yan Zhang, Yunyun Wang, Wenping Zhang
-
Patent number: 8530507Abstract: The use of levo-ornidazole in the preparation of medicine for preventing and treating the anti-anaerobic bacteria infection is provided. It is demonstrated that levo-ornidazole exhibits lower toxicity and less central inhibition effects than dextro-ornidazole or racemic ornidazole. L-ornidazole possesses pharmacokinetics characteristics, which are superior to that of the racemic ornidazole, and anti-anaerobic activities which are slightly better than or substantially the same as that of the racemic ornidazole. Also, this invention particularly relates to a preparation process, which comprises formulating L-ornidazole as anti-anaerobic infection pharmaceutical preparations, which are suitable for clinical uses.Type: GrantFiled: April 17, 2006Date of Patent: September 10, 2013Assignee: Nanjing Sanhome Pharmaceutical Co., Ltd.Inventors: Yong Wang, Cang Zhang, Zaijin Teng, Li Li
-
Publication number: 20110070192Abstract: Processes for the preparation of racemic and optically active nucleoside analogs of formula (A) are described. These compounds are useful as anti-infective agents, antisense therapeutic agents and hybridization assay probes.Type: ApplicationFiled: November 8, 2004Publication date: March 24, 2011Inventors: Bruno Tse, Borcherng Hong, Wei-Hung Chen, Yea-Fen Jiang, Shuo-Cang Zhang, Subramanian Marappan, Sepehr Sarshar
-
Publication number: 20100204324Abstract: An optically active N-(?-mercaptopropionyl)glycine, i.e., R-(?)-N-(?-mercaptopropionyl)glycine or S-(?)-N-(?-mercaptopropionyl)glycine, a preparation method thereof, a pharmaceutical preparation containing the compound or a pharmaceutically acceptable salt or ester thereof, and use of the same in preparation of detoxification medicament for improving metabolism, are provided.Type: ApplicationFiled: December 28, 2007Publication date: August 12, 2010Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.Inventors: Yong Wang, Cang Zhang, Zaijin Teng, Wenping Zhang, Jinye Qian
-
Publication number: 20090326030Abstract: The use of levo-ornidazole in the preparation of medicine for preventing and treating the anti-anaerobic bacteria infection is provided. It is demonstrated that levo-ornidazole exhibits lower toxicity and less central inhibition effects than dextro-ornidazole or racemic ornidazole. L-ornidazole possesses pharmacokinetics characteristics, which are superior to that of the racemic ornidazole, and anti-anaerobic activities which are slightly better than or substantially the same as that of the racemic ornidazole. Also, this invention particularly relates to a preparation process, which comprises formulating L-ornidazole as anti-anaerobic infection pharmaceutical preparations, which are suitable for clinical uses.Type: ApplicationFiled: April 17, 2006Publication date: December 31, 2009Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.Inventors: Yong Wang, Cang Zhang, Zaijin Teng, Li Li
-
Publication number: 20080177083Abstract: The use of levo-ornidazole in the preparation of anti-parasitic infection drug is provided. It is demonstrated that levo-ornidazole is superior to dextro-ornidazole and racemic ornidazole in the therapeutic action against parasitization (especially trichomonas vaginalis infection and cecal amoeba infection), and thus it is more practicable to formulate L-ornidazole as anti-parasitic infection drugs, and particularly as drug preparations which are suitable for clinical uses, including oral preparation, intravenous preparation and vaginal preparation.Type: ApplicationFiled: June 5, 2006Publication date: July 24, 2008Applicant: NANJING SANHOME PHARMACEUTICAL CO., LTD.Inventors: Yong Wang, Cang Zhang, Xiaoxin Tao